NASPGHAN 2025 Marks Major Shift in Celiac Disease Care & Research

For the first time, the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) dedicated an entire Single Topic Symposium to celiac disease, an autoimmune condition that affects roughly 1 in 100 children but remains frequently missed or diagnosed late. More than 350 clinicians, researchers, dietitians, and mental health professionals attended, reflecting growing recognition that celiac disease requires earlier detection, better follow-up care, and broader clinical expertise beyond specialty centers.

Speakers highlighted several key problems driving underdiagnosis, including persistent disparities in testing among children from lower-income and minority communities. Experts emphasized that screening is especially critical in children with related autoimmune conditions such as Type 1 diabetes and autoimmune thyroid disease, where risk is significantly higher.

Sessions also covered practical challenges pediatricians face when evaluating symptoms, deciding when to perform a gluten challenge, and interpreting inconsistent biopsy or antibody results. The symposium underscored that accurate diagnosis is central to preventing years of uncertainty and avoiding unnecessary dietary restriction.

Emerging research presented at the meeting pointed to major changes ahead: microbiome-targeted therapies, immune-modulating drugs, AI-supported diagnostics, and new clinical trial designs centered on quality of life. For families, these advances signal a future in which celiac disease may be easier to identify, treat, and manage, and one where strict lifelong gluten avoidance may no longer be the only option.